Tyrosine kinase inhibitorFDA-approvedSecond-line
Trametinib
How it works
Blocks the MEK protein, which is involved in cancer cell growth and survival, allowing the cancer cells to die.
Cancer types
Melanoma— BRAF V600E mutation
Efficacy
Studies show that around 50% of patients achieved an objective response, with a median progression-free survival of approximately 4.8 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Dabrafenib and Trametinib Rollover Study for Various Cancers | Lung Cancer | preclinical | — | Source → |
| New Trial Investigates Treatment for Newly Diagnosed Juvenile Myelomonocytic Leukemia | Leukemia | phase-1 | — | Source → |
| Trametinib for Relapsed or Refractory Juvenile Myelomonocytic Leukemia | Leukemia | phase-2 | — | Source → |
| Trametinib Shows Promise for Ovarian Cancer Treatment | Ovarian Cancer | phase-3 | The median progression-free survival was 20.1 months in patients with high tumor pERK expression versus 5.6 months with standard-of-care treatment. | Source → |
| New Insights into Treating Low-Grade Ovarian Cancer | Ovarian Cancer | lab-study | — | Source → |
| Study Examines Treatment Options for Lung Cancer Patients with Specific Genetic Mutation | Lung Cancer | observational | Median progression-free survival was 7.5 months and median overall survival was 18.7 months in patients treated with dabrafenib and trametinib. | Source → |
| Comparing Treatments for Melanoma Patients | Melanoma | meta-analysis | Dabrafenib and trametinib improved recurrence-free survival (RFS) compared to anti-PD(L)1 therapies (hazard ratio [HR] 0.53, 95% CI, 0.40-0.70, P < .01). | Source → |
| Combining two cancer drugs may help overcome melanoma resistance | Melanoma | lab-study | — | Source → |
| Targeted Therapy Shows Promise in Treating Pediatric Melanoma | Melanoma | observational | — | Source → |
| Rare Eye Condition Linked to Cancer Treatment | Melanoma | observational | — | Source → |
| Trametinib Helps Young Children with Advanced Leukemia | Leukemia | phase-2 | The objective response rate was 50%. | Source → |
| Rare Lung Cancer Patient Responds to Dabrafenib and Trametinib | Lung Cancer | observational | — | Source → |
| Neoadjuvant dabrafenib and trametinib for stage III melanoma: 5-year results | Melanoma | phase-2 | At 5 years, recurrence-free survival was 40% (95% CI 27% to 60%), distant metastasis-free survival was 57% (95% CI 42% to 76%), and overall survival was 80% (95% CI 67% to 94%). | Source → |
| Rare but Life-Threatening Side Effect of Melanoma Treatment | Melanoma | observational | — | Source → |
| Combining Medications for Advanced Melanoma Shows Promise | Melanoma | phase-2 | The confirmed objective response rate was 29.2%. | Source → |
| Moxibustion May Enhance Effectiveness of Cancer Treatment | Breast Cancer | animal-study | The tumor inhibition rate was 50.67% in the combination group. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.